Literature DB >> 33728333

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.

Lu Tang1,2, Yinqiang Zhang1,2, Yu Hu1,2, Heng Mei1,2.   

Abstract

T cell exhaustion has been recognized to play an immunosuppressive role in malignant diseases. Persistent tumor antigen stimulation, the presence of inhibitory immune cells and cytokines in tumor microenvironment (TME), upregulated expression of inhibitory receptors, changes in T cell-related transcription factors, and metabolic factors can all result in T cell exhaustion. Strategies dedicated to preventing or reversing T cell exhaustion are required to reduce the morbidity from cancer and enhance the effectiveness of adoptive cellular immunotherapy. Here, we summarize the current findings of T cell exhaustion in hematological malignancies and chimeric antigen receptor T (CAR-T) immunotherapy, as well as the value of novel technologies, to inverse such dysfunction. Our emerging understanding of T cell exhaustion may be utilized to develop personalized strategies to restore antitumor immunity.
Copyright © 2021 Lu Tang et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33728333      PMCID: PMC7936901          DOI: 10.1155/2021/6616391

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  81 in total

Review 1.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

2.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

3.  Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.

Authors:  Bertram Bengsch; Andy L Johnson; Makoto Kurachi; Pamela M Odorizzi; Kristen E Pauken; John Attanasio; Erietta Stelekati; Laura M McLane; Michael A Paley; Greg M Delgoffe; E John Wherry
Journal:  Immunity       Date:  2016-08-02       Impact factor: 31.745

4.  Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia.

Authors:  Lu Tang; Jianghua Wu; Cheng-Gong Li; Hui-Wen Jiang; Min Xu; Mengyi Du; Zhinan Yin; Heng Mei; Yu Hu
Journal:  Clin Cancer Res       Date:  2020-01-07       Impact factor: 12.531

Review 5.  TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

Authors:  William C Dougall; Sema Kurtulus; Mark J Smyth; Ana C Anderson
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

7.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

8.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

Review 9.  Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.

Authors:  Hao Wang; Gurbakhash Kaur; Alexander I Sankin; Fuxiang Chen; Fangxia Guan; Xingxing Zang
Journal:  J Hematol Oncol       Date:  2019-06-11       Impact factor: 17.388

10.  TOX is a critical regulator of tumour-specific T cell differentiation.

Authors:  Andrew C Scott; Friederike Dündar; Paul Zumbo; Smita S Chandran; Christopher A Klebanoff; Mojdeh Shakiba; Prerak Trivedi; Laura Menocal; Heather Appleby; Steven Camara; Dmitriy Zamarin; Tyler Walther; Alexandra Snyder; Matthew R Femia; Elizabeth A Comen; Hannah Y Wen; Matthew D Hellmann; Niroshana Anandasabapathy; Yong Liu; Nasser K Altorki; Peter Lauer; Olivier Levy; Michael S Glickman; Jonathan Kaye; Doron Betel; Mary Philip; Andrea Schietinger
Journal:  Nature       Date:  2019-06-17       Impact factor: 49.962

View more
  4 in total

Review 1.  Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.

Authors:  Sanjay Chandrasekaran; Christopher Ronald Funk; Troy Kleber; Chrystal M Paulos; Mala Shanmugam; Edmund K Waller
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561

Review 2.  The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy.

Authors:  Yuki Fujiwara; Toshiki Kato; Futoshi Hasegawa; Muha Sunahara; Yoshie Tsurumaki
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-09

3.  Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells.

Authors:  Cheng Wei; Kangfu Xia; Yucheng Xie; Sishi Ye; Yanghui Ding; Zairu Liu; Rong Zheng; Jing Long; Qinchuan Wei; Yumei Li; Dongxia Yang; Xiaojun Xu; Ai Zhao; Jimin Gao
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

Review 4.  CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.

Authors:  Jiawen Huang; Xiaobing Huang; Juan Huang
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.